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Abstract
Introduction: Myopathy related to systemic sclerosis (Myo-SSc) is a disabling and unpredictable complication of
SSc. We assessed the predictive value of serum aldolase, creatine kinase (CK), alanine transaminase (ALT), aspartate
transaminase (AST) and C-reactive protein (CRP) to estimate the risk of developing Myo-SSc.
Methods: We enrolled 137 SSc patients without proximal muscle weakness in a prospective monocentric study to
follow them longitudinally over a four-year period. The risk of occurrence of Myo-SSc was ascertained according to
the European NeuroMuscular Centre criteria and was analyzed according to levels of plasma aldolase, CK,
transaminase enzymes and CRP at inclusion. Performance of each parameter to predict Myo-SSc occurrence was
assessed and compared with the others.
Results: The area under the receiver operating characteristic curves (ROC) of plasma aldolase for Myo-SSc
occurrence prediction was 0.80 (95% CI: 0.67 to 0.94, P < 0.001), which was higher than that of plasma CK (0.75,
P = 0.01), and that of ALT (0.63, P = 0.04). AST and CRP had no predictive value for Myo-SSc occurrence. The best
cut-off of aldolase for prediction of Myo-SSc occurrence within three years after inclusion was 9 U/L and higher
than the upper normality limit (7 U/L), unlike that of CK and ALT. Myo-SSc occurred more frequently in patients
whose plasma aldolase was higher than 9 U/L. Adjusted Hazard Ratio for patients with aldolase > 9 U/L was
10.3 (95% CI: 2.3 to 45.5), P < 0.001.
Conclusions: Increased plasma aldolase level accurately identified SSc patients with high risk to develop
subsequent Myo-SSc. This could help initiate appropriate treatment when the disabling muscle damage is still in a
reversible stage.
Introduction
Systemic sclerosis (SSc) is a connective tissue disease
characterized by microvasculature damages, immune sys-
tem dysfunction and excessive deposition of collagen in
skin and other organs [1]. The prevalence of muscle
involvement in SSc previously reported ranges widely
from 16% to 81% according to different diagnosis criteria
used for muscle involvement [2-4]. Proximal muscle
strength weakness is a hallmark of a severe form of myo-
pathy related to SSc (Myo-SSc) having a tangible impact
on the impairment of quality of life. Current investiga-
tions focused on the diagnosis and therapy in Myo-SSc,
and copy exactly those from idiopathic inflammatory
myopathies (IIM) [5]. However, the pathology pattern of
muscle in SSc is heterogeneous (from myositis to muscle
fibrosis) and different from those of IIM [3,6]. Available
therapies, including corticosteroids, immunosuppressive
agents and intravenous immunoglobulin, may slow down
the muscle inflammation progression to prevent muscle
strength deterioration [7,8], but early diagnosis is impor-
tant to avert irreparable muscle damages and progression
of myositis that leads to bedridden patients with Myo-
SSc becoming unresponsive to appropriate therapy.
Thus, there is a need to develop biomarkers that could
permit early identification of SSc patients who are in dan-
ger of having subsequent Myo-SSc. The goal is to provide
them with appropriate therapy on time.
A partially validated laboratory test to assess the activ-
ity of myopathies is to assay the muscle enzymes: creatine
kinase (CK), transaminase enzymes including aspartate
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transaminase (AST), and alanine transaminase (ALT) and
aldolase A, an isomer present in muscles, other isomers
(aldolase B and C) are present in brain or liver and are
not found in plasma, except in liver diseases. Elevated
serum or plasma levels of CK, transaminase enzymes or
aldolase A were observed in patients with SSc with
neither muscle weakness nor having engaged in any phy-
sical activities the days prior to the muscular enzymes
assay. This suggests that isolated increments may be
associated with underlying extended muscle damage and
may reflect the early stage of this muscle disease [9]. On
the other hand, in Myo-SSc, inflammatory cells and acti-
vated auto-reactive T cells contribute partly to muscle
damage. Increased inflammatory markers, such as
C-reactive protein (CRP), might also indirectly reflect
inflammatory muscle injury and could be a potential pre-
dictive marker of subsequent Myo-SSc occurrence.
Taken together, we hypothesized that muscle enzymes,
including aldolase A, CK, AST, ALT and CRP, could help
identify patients who were going to have subsequent dis-
abling Myo-SSc, but without proximal muscle weakness.
Therefore, in this prospective cohort study, we assessed




The inclusion period for this prospective monocentric
cohort study was from November 2004 to January 2007
in the Department of Internal Medicine, Saint Antoine
Hospital, University Paris VI, Paris, France, and the fol-
low-up of this time-to-event driven study ended in April
2010. Patients who met the following criteria were eligi-
ble for the study.
Inclusion criteria
Patients were considered eligible for inclusion if they
were older than 18 years and had a diagnosis of SSc,
according to the American College of Rheumatology cri-
teria [10]. The subsets of disease were defined according
to LeRoy’s criteria [11]. Patients treated by immunosup-
pressive therapy were also eligible. More importantly,
patients must not have had any proximal muscle weak-
ness. Muscle strength was checked according to the
eight manual muscle testing (8-MMT).
Eight manual muscle testing
8-MMT was used to check the muscle strength accord-
ing to the Medical Research Council scale [12,13] and
Kendall’s scale [14]. The intensity of the muscular deficit
was determined from the total quotation of eight mus-
cles: neck flexors, deltoid, biceps, psoas, maximus and
medius gluteus, and quadriceps. A training of 8-MMT
was performed before the beginning of the study.
Pr Cherin (P) taught physicians and physiotherapists to
score and to test muscle strength. To insure that proxi-
mal muscle involvement was symmetrical, we checked
the muscle strength bilaterally. If muscle strength was
not symmetrical, we used the most severe score of the
two sides. The variations of muscle strength score
between the two sides were less than 2%. The variation
between two observers was less than 4% during the
training period. The maximum score (normal muscle
power) is 80 points, and represents the unilateral muscle
strength score (70 points) plus the neck flexors strength
(10 points) according to Kendall scoring [14]. The mus-
cle strength was considered as normal if the 8-MMT
score was > 72 points. A proximal muscle weakness was
considered present, relevant and sustained if it was
observed by the investigator and physiotherapist per-
forming the 8-MMT with one month between the two
testings. If there was disagreement of more than 5% of
the 8-MMT score between the two tests at the same
visit, a third confirming testing was performed. The
mean value of the three 8-MMT was kept as the 8-
MMT score of the visit. To exclude SSc patients with
minor muscle involvement at the inclusion visit, only
the patients with normal muscle strength (8-MMT
score of > 72 points) were eligible for this cohort study.
An 8-MMT score of less than 72 points represents a
reduction of more than 10% of the normal muscle
power (80 points).
Exclusion criteria
Patients with proximal muscle weakness (8-MMT score
≤ 72) or known myositis were excluded. Those with the
following conditions that may increase blood aldolase,
AST, ALT, CK, and CRP were excluded: infection,
hypothyroidism, hepatitis, chronic haemolysis, recent
myocardial infarction (less than three months), or recent
leg or arm trauma. Patients who were unable to perform
correctly the initial muscle strength checking for any
reason were also excluded.
Data collection
The study was approved by the local ethics committee.
After written informed consent, patients underwent a
complete evaluation and the following data were col-
lected: age, gender, subtype of SSc, disease duration
(duration between the first non-Raynaud’s symptom and
date of enrolment).
Blood sample
Blood tests including serological testing for antinuclear
antibodies (ANA), antitopoisomerase I antibody (ATA),
anti-centromere antibody (ACA), anti-ribonucleoprotein
antibody (U1-RNP), and anti-polymyositis-scleroderma
antibody (PM-Scl) were performed. ANA were detected
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by indirect immunofluorescence using slides of mono-
layer Hep-2 cells (Kallestad, BioRad, Marnes la
Coquette, France) as the substrate. Seropositivity for
ANA was defined as 1:80 or higher. Centromere protein
B, antitopoisomerase I, U1-RNP, anti RNA polymerase
III and PM-Scl were identified by immunodot (Euroim-
mun, BioAdvance, Bussy Saint-Martin, France). We used
homemade immunodiffusion for Pm-Scl antibody, which
detects both anti-PMScl-100 and anti-PMScl-75. In
patients with myositis (n = 5), a discrepancy between
immunodiffusion and immunodot methods (that is,
immunodiffusion positive for anti Pm-Scl antibody and
immunodot positive for anti Pm-Scl-100 KDa antibody),
we have shown the presence of anti-PMScl-75 antibody
by dot blot method (Euroline myositis-antigen profil 3,
Euroimmun AG, Lubeck, Germany).
All sera were tested by homemade immunodiffusion
(ID) which detect both anti-PMScl-100 and anti-PMScl-
75, in case of discrepancy between immunodiffusion and
immunodot methods, detection of anti-PMScl 100 and
anti-PMScl-75 separately was performed by dot blot
(Euroline myositis-antigen profil 3, Euroimmun AG,
Lubeck, Germany).
Aldolase, creatine kinase and C reactive protein
measurements
Blood samples were collected by venipuncture on Li-
heparinate 5 mL tubes from patients after 72 h of resting
and an overnight fasting. Plasma aldolase and CK activities
were performed by enzymatic methods at inclusion and at
the diagnosis of myopathy. For aldolase determination, we
adapted a kit from Randox on Synchron CX-4 (Beckman-
Coulter, Brea, CA, USA) and using quality controls from
Roche, (Burgess Hill, United Kingdom); this assay mea-
sures only aldolase A (named aldolase), but not the other
isoforms, aldolases B and C. AST, ALT, CK activities and
CRP were measured on Olympus AU-800 (Olympus)
using commercial kits and both internal and external qual-
ity controls. The upper limits for plasma aldolase and CK
were 7 U/L and 160 U/L, respectively, as stated by the kit
manufacturers. The upper limit for CRP was 4 mg/L and
32 U/L for both transaminase enzymes (AST and) ALT in
females, but 35 U/L for AST and 43 U/L for ALT in
males.
Follow-up
Endpoint: occurrence of myopathy related to scleroderma
The occurrence of Myo-SSc was defined as events that
took place during the follow-up. Visits were scheduled
every year over a four-year period and more frequently
when clinically indicated. Weakness was defined by the
loss of eight points, representing a relative decrease of 10%
of the maximal score from baseline at the 8-MMT score.
We chose this magnitude of change to detect significant
muscle weakness requiring therapy. Changes in muscle
strength were assessed by 8-MMT at each visit by the phy-
sician. If the proximal muscle weakness (8-MMT score <
72) was present, the physiotherapist tested the patient
again within a month to insure the presence of sustained
muscle weakness [15].
Patients with a relevant proximal muscle weakness
underwent an electromyography (EMG) or/and a thigh
muscle resonance magnetic imaging (RMI) and/or a
muscle biopsy. The diagnosis of Myo-SSc was defined as
the presence of muscle weakness and at least two of the
three following criteria according to the 119th European
Neuromuscular Centre (ENMC) International Workshop
criteria [5]:
1. Electromyographic triad of myopathy on EMG:
low voltage and short duration potential, fibrillation
or sharp wave.
2. Characteristic features of muscle involvement in
thigh muscle RMI: hyperintense signal and enhance-
ment on STIR and fat-saturated gadolinium
enhanced T1 weight images.
3. Evidence of myositis in muscle biopsy specimen:
myofibre atrophy and necrosis/regeneration; inflam-
mation; fibrosis; microangiopathy; vasculitis invol-
ving small arteries; mitochondrial abnormalities and
neuropathic changes.
On the other hand, patients with normal muscle
strength were also followed up on a regular basis with one
visit a year and more frequently if symptoms required.
During the follow-up, patients were informed about their
plasma aldolase levels and the need to contact us if they
had a feeling of muscle weakness. The isolated increased
aldolase level does not induce a change of medication or
behavior in the treating physician. At the additional visit,
we performed 8-MMT again. Only patients with reduction
of muscle strength of more than 10% from the baseline
score of 8-MMT required further investigations for
myositis.
Statistical analysis
All data are given as mean ± standard deviation (SD)
and percentage for continuous variables and categorical
variables respectively. A P-value < 0.05 was considered
as statistically significant.
We used receiver operating characteristic curves (ROC)
analysis to assess both the optimal threshold with the
highest Youden index and the diagnostic performance of
muscular enzymes, which identified SSc patients who
were going to have subsequent disabling Myo-SSc within
the three years after inclusion (positive if Myo-SSc
occurred within three years of follow-up and negative if
Myo-SSc did not occur).
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Second, SSc patients were categorized into two
groups: patients with muscular enzymes levels higher
than the best threshold and the remaining patients. To
estimate the predictive value of muscular enzymes on
subsequent Myo-SSc occurrence during the whole fol-
low-up, cumulative risks were computed using the
Kaplan-Meier analysis. We used Cox proportional
hazard model multivariate analysis to assess the risk of
developing Myo-SSc for patients according to the
plasma level of pertinent predictive biomarkers at inclu-
sion. Odds-ratios for Myo-SSc occurrence according to
pertinent predictive biomarkers were estimated by the
Cox proportional hazard model.
For all parameters, the conformity with proportional
hazards assumption was tested by linear regression of
Schoenfeld residuals on the time variable in observations
with event = 1. For categorical parameters, the conformity
with proportional hazards assumption was verified graphi-
cally and, in addition, by Kaplan Meier curves construc-
tion. Only parameters fulfilling the proportional hazards
assumption were used in the Cox analysis.
Results
Characteristics of population at baseline
One hundred, fifty patients with SSc were eligible in this
prospective study. Four SSc patients with systemic infec-
tion and nine other patients who were unable to complete
muscle strength checking procedure were excluded.
Among the nine SSc patients excluded for the presence of
proximal muscle weakness at inclusion, the diagnosis
Myo-SSc was made in four (Figure 1 illustrates the study
design). We thus included 137 patients consecutively in
the study (Table 1). The mean age was 54.8 ± 12.9 years.
The mean disease duration was 12.2 ± 12.0 years. The rate
of the diffuse form of disease was 31%. Fifty-six percent of
patients experienced myalgia. Thirty-seven among 137
patients had ATA, 62 had ACA, 8 had U1-RNP antibody,
6 patients U3-RNP antibody, 5 patients anti-PM-Scl anti-
body and 4 anti-RNA polymerase III. Any discrepancy
between immunodiffusion and immunodot methods for
Pm-Scl antibody was detected. The mean level of CRP was
5.2 ± 7.6 mg/L. Mean levels of aldolase and CK were 10.3
± 7.5 U/L and 111.1 ± 142.1 U/L, respectively. During a
mean follow-up period of 45.3 ± 17.4 months, no patient
was lost. Among 14 patients with SSc who experienced
proximal muscle weakness during the follow-up, 5 had
transient proximal muscle weakness and 9 had Myo-SSc
according to the 119th ENMC International Workshop cri-
teria (Table 2) [5]. The 8-MMT score from five SSc
patients fluctuated during the follow-up. We performed
EMG and RMI in these five patients. EMG and RMI
showed no abnormality consistent with a myositis. We
retested these five patients in the subsequent scheduled
visits. Their 8-MMT score became higher than 72 points.
Performances of muscular enzymes to predict subsequent
myopathy related to SSc occurring three years after
inclusion
The baseline plasma levels of aldolase ranged from 2 U/L
to 40 U/L, those of CK from 22 U/L to 900 U/L, those of
ALT from 6 U/L to 110 U/L and those of AST from 10 U/
L to 60 U/L. The area under ROC curves (AUROCs) of
aldolase and CK values for identifying subsequent Myo-
SSc occurrence were 0.80 (95% CI: 0.67 to 0.94; P <
0.001), and 0.75 (95% CI: 0.49 to 1.0; P = 0.01), respec-
tively. The AUROCs of ALT and AST values for identify-
ing subsequent Myo-SSc occurrence were 0.63 (95% CI:
0.46 to 0.81; P = 0.04), and 0.57 (95% CI: 0.35 to 0.79; P =
0.14), respectively. The prediction power of plasma aldo-
lase level for identifying subsequent Myo-SSc occurrence
was significantly higher than those of CK, and those of
transaminase enzymes (ALT, AST) but the difference
between the two AUROCs was not statistically significant
(P = 0.01). By contrast, CRP (AUROC = 0.48 for 95% CI:
0.28 to 0.70; P = 0.27) had no predictive value for Myo-
SSc occurrence.
Thresholds of muscular enzymes to predict subsequent
myopathy related to SSc occurring three years after
inclusion
The best cut-off of aldolase for prediction of subsequent
Myo-SSc occurrence within three years after inclusion
was 9 U/L (95% CI: 3.5 to 20.0) with a sensitivity of 89%
(95% CI: 52% to 99%) and a specificity of 67% (58% to
75%). The best cut-off of CK, ALT and AST for identify-
ing patients with high risk of developing Myo-SSc within
three years after inclusion were 92 U/L (24.1 to 259.4),
18.0 U/L (9.7 to 32.7), and 25.0 U/L (13.2 to 39.2),
respectively. These cut-offs were all below its upper limit
of the normal level (the upper limit of the normal level of
CK was 160 U/L, those of ALT and AST were 32 U/L
and 32 U/L in females, 35 U/L and 43 U/L in males,
respectively.
Association between aldolase at baseline and subsequent
Myo-SSc occurrence
Systemic sclerosis patients whose aldolase level at base-
line was higher than 9 U/L were more likely to develop
subsequent Myo-SSc within the three years of the course
of disease (Figure 2). Clinical features and the presence of
anti-PM-Scl antibody, anti-U1-RNP antibody, anti-U3-
RNP antibody and anti RNA polymerase III antibody
known as auto-antibodies associated with Myo-SSc,
could not predict the subsequent Myo-SSc occurrence.
In an unadjusted Cox model, aldolase had a predictive
value on subsequent Myo-SSc occurrence (Hazard ratio
(HR) = 11.1; 95% CI: 2.8 to 44.5, P < 0.001). In a Cox pro-
portional hazards model adjusted for age, gender, and
form and duration of disease, patients with aldolase
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higher than 9 UI/L had a higher risk of developing subse-
quent Myo-SSc occurrence (Hazard ratio (HR) = 10.3,
95% CI: 2.3 to 45.5; P < 0.001, Table 3).
Changes in muscular enzymes and CRP from baseline to
the diagnosis of Myo-SSc
Plasma aldolase A from all patients remained higher than
the upper limit of normality from inclusion to diagnosis
of Myo-SSc and the trend was towards an increasing
aldolase A level from baseline to the moment of Myo-
SSc diagnosis except in two patients. AST and CK
increased when the proximal strength weakness
appeared. ALT levels were fluctuating between the inclu-
sion and the moment of Myo-SSc diagnosis (Table 2).
Influence of immunosuppressive therapy on the
occurrence of Myo-SSc and its evolution
At inclusion, 18 SSc patients (13%) had immunosup-
pressive therapy. Six out of nine patients with Myo-SSc
were treated with immunosuppressive agents before
the diagnosis of Myo-SSc (Figure 1). At the time of
final assessment, 40 patients (26.3%) out of 137 had
immunosuppressive therapy (Methotrexate, cyclopho-
sphamide, or mycophenolate mofetil) for recent lung
function deterioration, or arthritis during the follow-up
period. Among 22 patients who had newly immuno-
suppressive therapy during the follow-up, none had
myositis.
All Myo-SSc patients had immunosuppressive therapy
and intravenous immunoglobulin after diagnosis. Three
out of nine normalized the 8-MMT score and aldolase
levels. Although combining therapy, six remaining
patients with myositis worsened, and three died due to
acute respiratory failure (n = 2), and bacterial septicemia
related to intestinal pseudo-obstruction with severe mal-
nutrition (n = 1). Consecutive plasma aldolase levels
from the six other Myo-SSc patients remained higher
than the upper limit of normal value.
Figure 1 Details of enrolment and flow of patients in the study.
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Discussion
In this cohort study, we found that elevated plasma
aldolase at inclusion was an accurate marker that helped
to identify SSc patients without muscle weakness who
were going to develop subsequent Myo-SSc during the
follow-up period. Thus, the best threshold of aldolase
for prediction of Myo-SSc occurrence within three years
after inclusion was 9 U/L. As opposed to aldolase, ele-
vated plasma CK or ALT had weaker performance for
prediction of subsequent Myo-SSc occurrence in SSc,
especially because their respective thresholds were
below the upper limit of measurement method and
made them unreliable to discriminate SSc patients with
high risk from those with low risk. Moreover, AST and
CRP were not able to predict subsequent Myo-SSc
occurrence.
Clements et al. [16] suggested that there are two pat-
terns of muscle involvement: on one hand, “simple myo-
pathy”, a non-progressive form of myopathy with
normal or slight elevation of muscular enzymes charac-
terized by muscle atrophy without inflammation; on the
other hand, “scleromyositis”, a progressive form with
profound proximal muscle weakness, significant eleva-
tion of muscular enzymes, EMG abnormality and
inflammatory myopathy in muscle biopsy specimens.
Although these two patterns of myopathy are still rele-
vant in the clinical setting, the design of our present
study was aimed to diagnose the latter disabling form of
My which needs corticosteroids and immunosuppressive
therapy [3]. Our findings are consistent with the hypoth-
esis that there is a gradual transition in the course of




Age (years) 54.8 ± 12.9
Female, n (%) 125 (91.2)
Duration of SSc disease (years) 12.2 ± 12.0
Diffuse, n (%) 42 (31)
Modified Rodnan skin score 8.1 ± 6.0
Myalgia, n (%) 77 (56)
DLCO (% pred) 64 ± 17
ILD, n (%) 51 (37.1)
ATA, n (%) 37 (27)
ACA, n (%) 62 (45)
Anti U1-RNP antibody 8 (5.8)
Anti U3-RNP antibody 6 (4.3)
Anti PM-Scl antibody 5 (3.6)
Anti RNA polymerase III antibody 4 (2.9)
C-reactive protein (mg/L) 5.2 ± 7.6
Plasma aspartate transaminases (0 to
32 U/L)
23.1 ± 9.3
Plasma alanine transaminases (0 to 32
U/L)
21.5 ± 14.0
Plasma aldolase (0 to 7 U/L) 10.3 ± 7.5
Plasma creatine kinase (0 to 160 U/L) 111.1 ± 142.1
Immunosuppressive treatment, n (%) 18 (13)
% of pred, percentage of predicted value; ACA, Anti-centromere antibodiy;
U3-RNP, Anti U3-RNP antibody; anti-PM-Scl, anti-polymyositis-scleroderma
antibody; ATA, Anti-topoisomerase I antibody; DLCO, diffusing capacity of
carbon monoxide; ILD, interstitial lung disease; PM-Scl, polymyositis
scleroderma; sPAP, Systolic pulmonary artery pressure assessed by
echocardiogram; U1-RNP, U1-ribonucleic protein. Among 18 patients with
immunosuppressive therapy, nine had corticosteroid dose less than 10 mg/
day.
Table 2 Clinical features at diagnosis of patients with myopathy related to systemic sclerosis
N
°

































1 dSSc ATA 16 38 12 34 66 19 172 49 800 + - +
2 dSSc ATA 9 35 20 11 60 9.7 58 28 234 + - +
3 lSSc ACA 15.8 36 24 25 64 40 86 32 100 - + +
4 lSSc ATA 23.5 25 31 31 55 9.3 53 25 364 + + +
5 lSSc ACA 29 55 54 18 68 37.2 962 22 1,180 + + +
6 dSSc ATA
PM-Scl
9.3 56 29 36 66 22.4 122 99 254 + + +
7 dSSc ATA
U3-RNP
16.2 54 14 21 68 17.8 109 52 271 + + +
8 lSSc ACA 13.6 50 16 19 64 24.8 173 96 40 + + ND
9 dSSc 0 11.6 14 15 14 69 9.1 57 20 28 + + ND
+ means the presence of abnormalities described as criteria of myositis according to the EMNC (5); ACA, Anti-centromere antibodiy; ATA, Anti-topoisomerase I
antibody; CK, creatine kinase; dSSc, diffuse form of systemic sclerosis; all patients had antinuclear antibody positive; EMG, electromyography; lSSc, limited
cutaneous form of systemic sclerosis; ND, not done; PM-Scl, anti- polymyositis-scleroderma antibody; RMI, resonance magnetic imaging; U3-RNP, Anti U3-RNP
antibody; Yrs, years
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muscle involvement in SSc from early muscle damage
related to inflammatory processes to the late stage of
muscle atrophy and fibrosis leading to a proximal mus-
cle weakness. As aldolase is a highly sensitive marker of
muscle damage, the release of a high amount of this
enzyme in blood plasma from SSc patients with normal
muscle strength may reflect underlying muscle injury
that herald severe Myo-SSc occurrence and may be used
as an early sign of this disease.
Currently, patients with SSc have multiple complaints,
including myalgia, skin hardening, joint pain or arthritis,
that make the diagnosis of Myo-SSc more difficult and
may even delay the diagnosis. To date, there is no rele-
vant predictive marker available for Myo-SSc. Previous
reports suggested that an increased aldolase level in
patients with Myo-SSc reflect both the activity and
severity of the myopathy [9,17,18]. Here, we provide
clinical evidence that aldolase may be useful as a predic-
tive marker of subsequent Myo-SSc occurrence in SSc
patients without proximal muscle weakness. Indeed,
patients with aldolase levels above 9 U/L were more
likely to develop subsequent Myo-SSc. Hence, elevated
aldolase in patients with SSc may be used by clinicians
to monitor a close follow-up to choose the right time to
perform invasive investigations, such as muscle biopsy,
yielding critical information, allowing them to make
early diagnosis of Myo-SSc and to give appropriate ther-
apy [6]. Other muscular enzymes, including CK, ALT
and AST, were not accurate in predicting the subse-
quent Myo-SSc occurrence.
The rate of anti-PM-Scl antibody found in this present
study was consistent with that recently reported by
Hanke et al. [19], but lower than that reported by others
[20-22]. We did not find a discrepancy between immu-
nodiffusion and immunodot methods for Pm-Scl anti-
body, suggesting indirectly the presence of isolated anti-
PMScl-75 kDa antibody. However, the presence of anti-
bodies against antitopoisomerase I, anti-centromere,
anti-ribonucleoprotein or PM-Scl did not predict the
subsequent Myo-SSc occurrence. This is at odds with
the previous results, showing that patients with anti-
PM-Scl antibody had pejorative prognosis in IIM [23].
Figure 2 Kaplan Meier analysis grouped by baseline aldolase. The black line represents the group of SSc patients with baseline plasma
aldolase level above 9 U/L and the dotted grey line the group of SSc patients with baseline plasma aldolase level equal or below 9 U/L.
Table 3 Risk subsequent muscular involvement according





Aldolase > 9 U/L 10.3 (2.3 to 45.5) <
0.001
Age (per additional year) 0.98 (0.93 to 1.04) 0.68
Female 0.63 (0.07 to 5.18) 0.67
Diffuse form of disease 1.23 (0.27 to 5.49) 0.78
Duration of disease (per additional
year)
0.97 (0.90 to 1.05) 0.57
Upper limit of plama aldolase value: 7.0 UI/L
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The presence of anti-PM-Scl antibody could not esti-
mate the risk of developing Myo-SSc in patients with
SSc.
Proximal muscle weakness is a hallmark of myositis
associated with connective tissue disease, and current
available therapies attempt to restore muscle strength.
Although the diagnosis criteria of Myo-SSc are not yet
fully codified, they rely primarily on the proximal mus-
cle weakness and require association with at least two of
the three others criteria defined by the 119th ENMC
International Workshop [5]. Although muscle biopsy
specimens from two patients with Myo-SSc were not
available, all nine patients fulfilled myositis associated
with connective tissue disease according to the 119th
ENMC International Workshop criteria [5].
One might argue that other factors, including physical
activity and/or trauma, may contribute to elevation of
plasma aldolase. In this study, aldolase was assessed in
patients after 72 hours of resting, and overnight fasting.
For obvious ethical reasons, we could not obtain muscle
tissue to provide direct histological evidence showing
myopathy or myositis in patients without proximal mus-
cle weakness and isolated increase of aldolase. There is,
however, circumstantial evidence, stemming from pre-
vious studies in SSc patients with Myo-SSc, that partly
explain our findings. In particular, an autopsy study
found inflammatory muscles in 9% of patients with SSc
[24], with different patterns of myopathy; this suggests a
continuum spectrum between the slight elevation of
aldolase and “scleromyositis” during the course of
disease.
Our study had several limits. First, consistently with a
recent report [25], the incidence of Myo-SSc with proxi-
mal muscle weakness during a mean follow-up was low
(6.6% in 45.3 months of follow-up), which may explain
the wide range of hazard ratio. Second, although we
provided accurate thresholds of aldolase for prediction
of Myo-SSc occurrence, external validation by an inde-
pendent cohort is needed prior to recommended inter-
vention studies targeting aldolase in SSc. Third, we
might neglect some early stage of myositis, but the
annual visits scheduled and additional visits if symptoms
occurred minimize the risk of misdiagnose mild
myositis.
Conclusion
Our findings show that increased plasma aldolase is a
non-invasive and valuable means of identifying SSc
patients with high risk of developing subsequent Myo-
SSc. This would allow clinicians to monitor these at-risk
patients and to diagnose Myo-SSc at an early stage. This
would allow clinicians to initiate appropriate treatments
when the muscle damage is still in a reversible stage.
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